Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Shares Outstanding for 14 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 36.03% year-over-year to $29.0 million, compared with a TTM value of $29.0 million through Dec 2025, up 36.03%, and an annual FY2025 reading of $21.4 million, up 0.91% over the prior year.
  • Shares Outstanding was $29.0 million for Q4 2025 at Enanta Pharmaceuticals, up from $21.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $29.0 million in Q4 2025 and bottomed at $20.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $21.3 million, with a median of $21.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 0.6% in 2024, then soared 36.03% in 2025.
  • Year by year, Shares Outstanding stood at $20.5 million in 2021, then grew by 1.84% to $20.9 million in 2022, then rose by 1.3% to $21.2 million in 2023, then grew by 0.84% to $21.3 million in 2024, then skyrocketed by 36.03% to $29.0 million in 2025.
  • Business Quant data shows Shares Outstanding for ENTA at $29.0 million in Q4 2025, $21.4 million in Q3 2025, and $21.4 million in Q2 2025.